Healthcare resource use of patients with transthyretin amyloid cardiomyopathy

Lauppe, Rosa; Hansen, Johan Liseth; Fornwall, Anna; Johansson, Katarina; Rozenbaum, Mark H; Strand, Anne Mette; Väkeväinen, Merja; Gude, Einar; Smith, Josh; Gustafsson, Finn

doi:10.1002/ehf2.13913

Cited by 5 publications

(3 citation statements)

References 23 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The high healthcare cost of ATTR-CM compared to other types of heart failure is also in line with the findings of Lauppe et al. [ 21 ], who demonstrated higher healthcare resource use among Scandinavian ATTR-CM patients than among matched heart failure patients without ATTR-CM. The study by Lauppe et al.…”

Section: Discussionsupporting

confidence: 88%

“…Recent studies in Scandinavia have shown that ATTR-CM imposes a considerable burden on the healthcare system [ 21 , 22 ] with more hospitalization and outpatient visits compared to other causes of heart failure [ 21 ]. However, studies investigating healthcare resource use and costs in relation to the different stages of heart failure progression are lacking.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden

Hjalte,

Norlin,

Alverbäck-Labberton

et al. 2023

Annals of Medicine

Self Cite

View full text Add to dashboard Cite

Aims To estimate healthcare resource use and direct healthcare costs of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Sweden over 12 months across severity stages as defined by the New York Heart Association (NYHA). Secondary to investigate the current diagnostic trajectory for patients with ATTR-CM in Sweden. Methods A stratified inclusion of patients with a confirmed diagnosis of ATTR-CM in different NYHA classes. Data was extracted from medical records in two cardiology clinics in Sweden. Healthcare resource use data were retrospectively collected for 12 months. Results 38 patients were included, of whom 7 were in NYHA class II, 20 in class III and 4 in class IV. The total cost of health care per patient increased from SEK 69,000 (€6800) in NYHA stage II, SEK 219,000 (€21,500) in NYHA stage III, to SEK 638,000 (€62,900) in stage IV, mainly due to an increase in inpatient stays. Mean time (standard deviation, SD) from any cardiac related diagnosis prior to ATTR-CM diagnosis was 3.5 (3.1) years. Conclusions Advanced ATTR-CM stages are associated with significant healthcare costs, as patients more often require resource-intensive inpatient care. The current diagnostic trajectory of ATTR-CM in this study was characterized by a diagnostic delay of several years.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden

Hjalte,

Norlin,

Alverbäck-Labberton

et al. 2023

Annals of Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“… 14 These delays can lead to disease progression, lack of or inappropriate treatment, and/or higher health care utilization in many patients. 28 Screening and targeted testing to enhance early diagnosis is critical, as improper or delayed diagnosis can have prognostic and therapeutic implications. Ensuring appropriate and timely diagnosis and treatment, especially in advanced disease, is paramount to allow patients to benefit from earlier access to new disease-modifying therapies.…”

Section: Discussionmentioning

confidence: 99%

Transthyretin Amyloid Cardiomyopathy Risk Evaluation in a Cohort of Patients With Heart Failure

Suh

Shaw

Jeong

et al. 2023

TPJ

View full text Add to dashboard Cite

Introduction Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, infiltrative form of heart failure (HF). Nevertheless, ATTR-CM is a largely underrecognized and misdiagnosed condition. This study’s objective was to develop an efficient model to assess the chance of ATTR-CM in patients with HF. Methods This was an observational study of patients with HF who had a confirmed diagnosis of ATTR-CM and those with HF but without known ATTR-CM between January 1, 2019, and July 1, 2021. Patient characteristics were extracted from administrative and claims electronic databases and compared between the groups. A propensity score for having ATTR-CM was modeled. Samples of 50 control patients with the highest and lowest propensity scores were adjudicated to assess whether further workup to evaluate for ATTR-CM was warranted for each patient. The sensitivity and specificity of the model were calculated. Results Thirty-one patients with confirmed ATTR-CM and 7620 patients without known ATTR-CM were included in the study. Patients with ATTR-CM were more likely to be Black and to have atrial flutter/fibrillation, cardiomegaly, HF with preserved ejection fraction, pericardial effusion, carpal tunnel syndrome, joint disorders, and lumbar spinal stenosis and to use a diuretic (all p < 0.05). A propensity model with 16 inputs was developed (c-statistic = 0.875). The model’s sensitivity and specificity were 71.9% and 95.2%, respectively. Conclusion The propensity model developed in this study provided an efficient means for identifying patients with HF who are more likely to have ATTR-CM and may warrant further workup.

show abstract

Healthcare resource use of patients with transthyretin amyloid cardiomyopathy

et al. 2022

Self Cite

View full text Add to dashboard Cite

Aims Transthyretin amyloid cardiomyopathy (ATTR-CM) is the cardiac manifestation of transthyretin amyloidosis (ATTR).The aim of this study was to estimate healthcare resource use for ATTR-CM patients compared with heart failure (HF) patients, in Denmark, Finland, Norway, and Sweden. Methods and results Data from nationwide healthcare registers in the four countries were used. ATTR-CM patients were defined as individuals diagnosed with amyloidosis and cardiomyopathy or HF between 2008 and 2018. Patients in the ATTR-CM cohort were matched to patients with HF but without ATTR-CM diagnosis. Resource use included number of visits to specialty outpatient and inpatient hospital care. A total of 1831 ATTR-CM and 1831 HF patients were included in the analysis. The mean number of hospital-based healthcare contacts increased in both the ATTR-CM and HF cohort during 3 years pre-diagnosis and was consistently higher for the ATTR-CM cohort compared with the HF cohort, with 6.1 [

show abstract

Healthcare resource use of patients with transthyretin amyloid cardiomyopathy

Cited by 5 publications

References 23 publications

Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden

Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden

Transthyretin Amyloid Cardiomyopathy Risk Evaluation in a Cohort of Patients With Heart Failure

Healthcare resource use of patients with transthyretin amyloid cardiomyopathy

Contact Info

Product

Resources

About